drugset
drugset / Trial / NCT06285825

A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged Cytopenia

NCT06285825 ↗

Phase 2 Recruiting 32 enrolled M.D. Anderson Cancer Center Sobi, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

To look at the safety and effectiveness of emapalumab for the treatment of prolonged severe cytopenia in participants with LBCL who receive CART.

Timeline

Start
2024-07-05
Primary completion
2026-08-22
Completion
2028-08-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Emapalumab Monoclonal antibody — Other

Indications

No indication recorded.